Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer's disease.
暂无分享,去创建一个
[1] Janet B W Williams. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[2] P. Calabresi,et al. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. , 2011, Journal of Alzheimer's Disease.
[3] W. M. van der Flier,et al. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations , 2010, Journal of Neurology, Neurosurgery & Psychiatry.
[4] I. Ferrer,et al. Aβ accumulation in choroid plexus is associated with mitochondrial-induced apoptosis , 2010, Neurobiology of Aging.
[5] L. Minthon,et al. Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease , 2010, Alzheimer's Research & Therapy.
[6] K. Eguchi,et al. Development of an Ultra-Rapid Diagnostic Method Based on Heart-Type Fatty Acid Binding Protein Levels in the CSF of CJD Patients , 2010, Cellular and Molecular Neurobiology.
[7] A. Hofman,et al. Matrix metalloproteinase 3 haplotypes and plasma amyloid beta levels: The Rotterdam Study , 2010, Neurobiology of Aging.
[8] P. Mariën,et al. Neurobiochemical markers of brain damage in cerebrospinal fluid of acute ischemic stroke patients. , 2010, Clinical chemistry.
[9] J. O'Brien,et al. Quantification of myelin loss in frontal lobe white matter in vascular dementia, Alzheimer’s disease, and dementia with Lewy bodies , 2010, Acta Neuropathologica.
[10] C. Humpel,et al. Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1–42 levels , 2009, Neuroscience Letters.
[11] K. Blennow,et al. Subcortical Vascular Dementia Biomarker Pattern in Mild Cognitive Impairment , 2009, Dementia and Geriatric Cognitive Disorders.
[12] T. Nabeshima,et al. Matrix Metalloprotease-9 Inhibition Improves Amyloid β-Mediated Cognitive Impairment and Neurotoxicity in Mice , 2009, Journal of Pharmacology and Experimental Therapeutics.
[13] J. Montaner,et al. Neuronal TIMP‐1 release accompanies astrocytic MMP‐9 secretion and enhances astrocyte proliferation induced by β‐amyloid 25–35 fragment , 2009, Journal of neuroscience research.
[14] J. Montaner,et al. Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study. , 2009, Journal of proteome research.
[15] E. Candelario-Jalil,et al. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia , 2009, Neuroscience.
[16] G. Rosenberg. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases , 2009, The Lancet Neurology.
[17] H. Nagase,et al. Progress in matrix metalloproteinase research. , 2008, Molecular aspects of medicine.
[18] T. Joh,et al. A novel intracellular role of matrix metalloproteinase‐3 during apoptosis of dopaminergic cells , 2008, Journal of neurochemistry.
[19] K. Nozaki,et al. Tissue Inhibitor of Metalloproteinases Protect Blood—Brain Barrier Disruption in Focal Cerebral Ischemia , 2008, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[20] S. Love,et al. Abeta-degrading enzymes in Alzheimer's disease. , 2008, Brain pathology.
[21] E. Lo,et al. Multiphasic roles for matrix metalloproteinases after stroke. , 2008, Current opinion in pharmacology.
[22] E. Tsilibary,et al. Abeta(1–40)-induced secretion of matrix metalloproteinase-9 results in sAPPα release by association with cell surface APP , 2007, Neurobiology of Disease.
[23] M N Rossor,et al. A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia , 2007, Neurodegenerative Diseases.
[24] Jiankun Cui,et al. Hypoxia-inducible Factor 1α (HIF-1α)-mediated Hypoxia Increases BACE1 Expression and β-Amyloid Generation* , 2007, Journal of Biological Chemistry.
[25] Jin-Moo Lee,et al. Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ* , 2006, Journal of Biological Chemistry.
[26] B. Rosen,et al. Role of matrix metalloproteinases in delayed cortical responses after stroke , 2006, Nature Medicine.
[27] E. Lo,et al. Involvement of Matrix Metalloproteinase in Neuroblast Cell Migration from the Subventricular Zone after Stroke , 2006, The Journal of Neuroscience.
[28] B. Ahlemeyer,et al. PTEN: A crucial mediator of mitochondria-dependent apoptosis , 2006, Apoptosis.
[29] C. V. Jensen,et al. Acute axonal damage predicts clinical outcome in patients with multiple sclerosis , 2005, Multiple sclerosis.
[30] Jiankun Cui,et al. A Highly Specific Inhibitor of Matrix Metalloproteinase-9 Rescues Laminin from Proteolysis and Neurons from Apoptosis in Transient Focal Cerebral Ischemia , 2005, The Journal of Neuroscience.
[31] C. Haass,et al. Amyloid β-induced Changes in Nitric Oxide Production and Mitochondrial Activity Lead to Apoptosis* , 2004, Journal of Biological Chemistry.
[32] M. Obrenovich,et al. Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease? , 2004, Neurological research.
[33] J. Adair,et al. Measurement of Gelatinase B (MMP-9) in the Cerebrospinal Fluid of Patients With Vascular Dementia and Alzheimer Disease , 2004, Stroke.
[34] Kaj Blennow,et al. Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRX.
[35] E. Lo,et al. Role of Matrix Metalloproteinases in Delayed Neuronal Damage after Transient Global Cerebral Ischemia , 2004, The Journal of Neuroscience.
[36] A. Ghorpade,et al. Tissue inhibitor of metalloproteinase (TIMP)‐1: The TIMPed balance of matrix metalloproteinases in the central nervous system , 2003, Journal of neuroscience research.
[37] N. Norgren,et al. Elevated neurofilament levels in neurological diseases , 2003, Brain Research.
[38] D. Holtzman,et al. Matrix metalloproteinase–9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy , 2003, Annals of neurology.
[39] C. Haass,et al. Neurotoxic Mechanisms Caused by the Alzheimer's Disease-linked Swedish Amyloid Precursor Protein Mutation , 2003, Journal of Biological Chemistry.
[40] A. Wallin,et al. Classification and Subtypes of Vascular Dementia , 2003, International Psychogeriatrics.
[41] W. Hornebeck,et al. Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. , 2003, The Biochemical journal.
[42] S. Lorenzl,et al. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases , 2003, Journal of the Neurological Sciences.
[43] E. Lo,et al. Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury. , 2002, Journal of neurotrauma.
[44] K. Blennow,et al. Cerebrospinal Fluid Phospho-Tau, Total Tau and β-Amyloid1–42 in the Differentiation between Alzheimer’s Disease and Vascular Dementia , 2002, Dementia and Geriatric Cognitive Disorders.
[45] Leonardo Pantoni,et al. Pathophysiology of Age-Related Cerebral White Matter Changes , 2002, Cerebrovascular Diseases.
[46] J. Land,et al. β‐Amyloid inhibits integrated mitochondrial respiration and key enzyme activities , 2001, Journal of neurochemistry.
[47] K. Blennow,et al. Neurofilament protein in cerebrospinal fluid: A marker of white matter changes , 2001, Journal of neuroscience research.
[48] V. Wee Yong,et al. Metalloproteinases in biology and pathology of the nervous system , 2001, Nature Reviews Neuroscience.
[49] K. Blennow,et al. Both total and phosphorylated tau are increased in Alzheimer's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.
[50] T. Hattori,et al. Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. , 2001, Clinical neuropathology.
[51] M. Fini,et al. Role for Matrix Metalloproteinase 9 after Focal Cerebral Ischemia: Effects of Gene Knockout and Enzyme Inhibition with BB-94 , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[52] K. Blennow,et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization , 2000, Neuroscience Letters.
[53] H. Feldman,et al. The Diagnosis of “Mixed” Dementia in the Consortium for the Investigation of Vascular Impairment of Cognition (CIVIC) , 2000, Annals of the New York Academy of Sciences.
[54] G. Davies-Jones,et al. Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. , 2000, Brain : a journal of neurology.
[55] T. Hattori,et al. Selective distribution of matrix metalloproteinase-3 (MMP-3) in Alzheimer’s disease brain , 2000, Acta Neuropathologica.
[56] K. Blennow,et al. Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma , 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[57] J. Ogata. Vascular dementia: the role of changes in the vessels. , 1999, Alzheimer disease and associated disorders.
[58] T. Bates,et al. β‐Amyloid fragment 25–35 selectively decreases complex IV activity in isolated mitochondria , 1999, FEBS letters.
[59] G. Rosenberg,et al. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. , 1998, Stroke.
[60] A. Wallin. The Overlap between Alzheimer’s Disease and Vascular Dementia: The Role of White Matter Changes , 1998, Dementia and Geriatric Cognitive Disorders.
[61] V Hachinski,et al. The effect of different diagnostic criteria on the prevalence of dementia. , 1997, The New England journal of medicine.
[62] A. Clark,et al. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia , 1997, Neuroscience Letters.
[63] G. J. van der Vusse,et al. One-Step Enzyme-Linked Immunosorbent Assay (ELISA) for Plasma Fatty Acid-Binding Protein , 1997, Annals of clinical biochemistry.
[64] Joseph S. Beckman,et al. Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease , 1997, The Journal of Neuroscience.
[65] Michael J. Cullen,et al. Matrix Metalloproteinase-9 (MMP-9) Is Synthesized in Neurons of the Human Hippocampus and Is Capable of Degrading the Amyloid-β Peptide (1–40) , 1996, The Journal of Neuroscience.
[66] P. Gottschall,et al. Increased Production of Matrix Metalloproteinases in Enriched Astrocyte and Mixed Hippocampal Cultures Treated with β‐Amyloid Peptides , 1996 .
[67] W. O'Fallon,et al. Dementia after ischemic stroke , 1996, Neurology.
[68] N. Bersch,et al. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. , 1995, Blood.
[69] K. Blennow,et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.
[70] P. R. Hof,et al. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders , 1994, Acta Neuropathologica.
[71] A. Wallin,et al. Decreased myelin lipids in Alzheimer's disease and vascular dementia , 1989, Acta neurologica Scandinavica.
[72] H. Webster,et al. Immunocytochemical localization of basic protein in major dense line regions of central and peripheral myelin , 1982, The Journal of cell biology.
[73] S. Ohman,et al. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. , 1977, Scandinavian journal of clinical and laboratory investigation.
[74] A. Barrett,et al. The interaction of α2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism , 1973 .
[75] R. Friede,et al. Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice , 1970, The Anatomical record.
[76] L. Eriksson. Multi- and megavariate data analysis , 2006 .
[77] G C Roman,et al. Research criteria for subcortical vascular dementia in clinical trials. , 2000, Journal of neural transmission. Supplementum.
[78] K. Blennow,et al. Development of a Specific Diagnostic Test for Measurement of β-Amyloid (1-42) [βA4(l-42)] in CSF , 1998 .